Study guide
11.2 HER2-Positive Breast Cancer: Treatment Considerations
CBCN Certified Breast Care Nurse Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CBCN Exam
CBCN Exam Facts, 2026 Blueprint & Study Plan
2 Chapter 1: Breast Health, Examination & Benign Conditions (Care Continuum)
1.1 Breast Anatomy, Vascular Supply & Hormonal Physiology 1.2 Clinical Breast Examination & Breast Awareness Education 1.3 Benign Breast Conditions, Mastalgia & Fibrocystic Changes
3 Chapter 2: Screening, Breast Density & Special Populations (Care Continuum)
2.1 Screening Modalities, Breast Density & Pharmacologic Risk Reduction 2.2 Screening & Breast Health in Special Populations
4 Chapter 3: Cancer Risk Assessment & Genetics (Care Continuum)
3.1 Proliferative Lesions, Atypia & High-Risk Benign Pathology 3.2 Breast Cancer Risk Models (Gail, Tyrer-Cuzick, Claus, BRCAPRO) 3.3 Hereditary Cancer Syndromes & Genetic Evaluation
5 Chapter 4: Patient Navigation, Surveillance & Survivorship (Care Continuum)
4.1 Patient Navigation, Barriers to Care, Social Determinants & Interprofessional Collaboration 4.2 Survivorship Care Planning, Surveillance Intervals & Recurrence Monitoring 4.3 Secondary Prevention, Physical Activity, Nutrition & Wellness Guidance
6 Chapter 5: Carcinogenesis & Diagnostic Evaluation (Diagnosis and Staging)
5.1 Carcinogenesis: How Breast Cancer Develops and Spreads 5.2 Clinical Assessment, Diagnostic Imaging & BI-RADS Categorization 5.3 Breast Biopsy Modalities & Image-Guided Localization Techniques
7 Chapter 6: Pathology, Biomarkers & Genomic Testing (Diagnosis and Staging)
6.1 Histopathology: In Situ Carcinomas & Invasive Carcinoma Subtypes 6.2 Receptor Biomarkers (ER, PR, HER2, Ki-67) & Molecular Subtypes 6.3 Multigene Genomic Assays & Recurrence Risk Stratification
8 Chapter 7: Clinical & Pathologic Staging (Diagnosis and Staging)
7.1 AJCC TNM Staging System (Anatomic vs Prognostic Staging) 7.2 Staging Workup: When to Use MRI, CT, Bone Scan & PET
9 Chapter 8: Breast Surgery, Axillary Staging & Reconstruction (Treatment Modalities)
8.1 Breast-Conserving Surgery, Margin Standards & Mastectomy Techniques 8.2 Axillary Staging: Sentinel Lymph Node Biopsy vs. Axillary Dissection 8.3 Post-Mastectomy Reconstruction & Oncoplastic Surgery
10 Chapter 9: Radiation Therapy & Chemotherapy (Treatment Modalities)
9.1 Radiation Therapy: Whole Breast, Chest Wall, Regional Nodal & Partial Breast Irradiation 9.2 Neoadjuvant vs. Adjuvant Chemotherapy Principles & Standard Regimens
11 Chapter 10: Endocrine, HER2-Targeted & Novel Systemic Therapies (Treatment Modalities)
10.1 Endocrine Therapy: SERMs, Aromatase Inhibitors, Ovarian Suppression & SERDs 10.2 HER2-Targeted Monoclonal Antibodies, Antibody-Drug Conjugates & Kinase Inhibitors 10.3 CDK4/6 Inhibitors, PARP Inhibitors & Immune Checkpoint Blockade 10.4 Trop-2 Antibody-Drug Conjugates, PI3K/AKT/mTOR Inhibitors & New Oral SERDs
12 Chapter 11: Specific Conditions & Special Populations (Treatment Modalities)
11.1 Triple-Negative Breast Cancer: Treatment Considerations 11.2 HER2-Positive Breast Cancer: Treatment Considerations 11.3 Inflammatory Breast Cancer & Paget Disease of the Nipple 11.4 Phyllodes Tumors & Breast Angiosarcoma 11.5 Treatment Considerations for Special Populations
13 Chapter 12: Symptom Management & Supportive Care (Nursing Practice)
12.1 Acute Chemotherapy Toxicities, Supportive Regimens & Oncologic Emergencies 12.2 Lymphedema Pathophysiology, ISL Staging & Complete Decongestive Therapy (CDT) 12.3 Musculoskeletal Toxicities, Bone Health & Vasomotor/GSM Relief 12.4 Complementary & Integrative Modalities 12.5 Cancer Rehabilitation: Physical, Occupational & Pelvic Floor Therapy
14 Chapter 13: Oncologic Emergencies (Nursing Practice)
13.1 Oncologic Emergencies I: Spinal Cord Compression, Hypercalcemia, Tamponade & SVC Syndrome 13.2 Oncologic Emergencies II: Hypersensitivity & Anaphylaxis, Sepsis, Pleural Effusion & Thromboembolism
15 Chapter 14: Professional Practice, Clinical Trials & Self-Care (Nursing Practice)
14.1 Professional Practice: Guidelines, Ethics, Legislation, Outreach & Accreditation 14.2 Clinical Trials in Breast Oncology 14.3 Nurse Self-Care: Compassion Fatigue, Burnout, Moral Distress & Substance Use
16 Chapter 15: Psychosocial Dimensions of Care (Psychosocial Dimensions)
15.1 Psychosocial Distress, Coping, Grief & Palliative Care 15.2 Culture, Spirituality, Sexual & Gender Identity, Age & Healthcare Disparities 15.3 Family & Caregiver Dynamics 15.4 Altered Body Image 15.5 Reproductive & Sexual Health
11.2 HER2-Positive Breast Cancer: Treatment Considerations
Key Takeaways Explain This Topic AI
For small node-negative HER2-positive cancers, weekly paclitaxel for 12 weeks plus 1 year of trastuzumab (the APT regimen) produced about 91% invasive disease-free survival at 10 years.
HER2-positive tumors that are cT2 or larger or node-positive usually receive neoadjuvant chemotherapy with trastuzumab and pertuzumab before surgery.
After neoadjuvant therapy, a pathologic complete response leads to completing 1 year of HER2 therapy, while residual invasive disease leads to 14 cycles of ado-trastuzumab emtansine (KATHERINE).
Metastatic HER2-positive disease is treated first line with a taxane, trastuzumab, and pertuzumab (CLEOPATRA), then trastuzumab deruxtecan (DESTINY-Breast03), with tucatinib regimens favored for brain metastases.
Trastuzumab labeling advises effective contraception during treatment and for 7 months after the last dose because exposure in pregnancy can cause oligohydramnios.
Last updated: September 2026
Setting the Scene
HER2 is amplified or overexpressed in 15% to 20% of breast cancers. Before trastuzumab, HER2-positive disease had one of the worst prognoses; now it is among the most treatable subtypes. The drug details are in the HER2-targeted therapy section. Here the focus is on which pathway fits which patient and the nursing actions along the way.
Stage-Based Pathway
- Presentation Typical plan
- T1a N0 Individualized; HER2 therapy may be considered
T1b–T1c N0 (up to 2 cm, node-negative) Upfront surgery, then weekly paclitaxel × 12 plus trastuzumab for 1 year (APT regimen)
cT2 or larger, or node-positive Neoadjuvant chemotherapy with trastuzumab and pertuzumab (for example docetaxel-carboplatin-trastuzumab-pertuzumab, or an anthracycline followed by taxane plus HP)
Inflammatory or locally advanced Neoadjuvant chemotherapy plus HP, modified radical mastectomy, and radiation
The APT trial of paclitaxel plus trastuzumab reported about 91% invasive disease-free survival at 10 years in small node-negative cancers, supporting de-escalation for these patients.
Response-Adapted Adjuvant Therapy
After neoadjuvant therapy and surgery:
Pathologic complete response: complete 1 year of trastuzumab, with or without pertuzumab. Prognosis is excellent.
Residual invasive disease: switch to ado-trastuzumab emtansine (T-DM1) for 14 cycles; KATHERINE showed a 50% reduction in invasive disease or death compared with trastuzumab.
High-risk node-positive disease treated with upfront surgery: adjuvant chemotherapy with trastuzumab plus pertuzumab (APHINITY).
Extended therapy: for HR-positive, HER2-positive disease, 1 year of neratinib after trastuzumab (ExteNET) can be considered, with mandatory diarrhea prophylaxis or dose escalation.
Trastuzumab deruxtecan-based regimens are being studied in early disease, so check current approvals before assuming a standard.
HR-Positive, HER2-Positive Disease
About half of HER2-positive cancers are also HR-positive. After chemotherapy, these patients add endocrine therapy for 5 to 10 years, given alongside ongoing HER2 therapy. Ovarian function suppression applies to high-risk premenopausal patients as in HR-positive disease.
Metastatic HER2-Positive Disease
First line: a taxane with trastuzumab and pertuzumab (CLEOPATRA: median overall survival 56.5 versus 40.8 months).
Second line: trastuzumab deruxtecan (DESTINY-Breast03), with vigilance for interstitial lung disease.
Later lines and brain metastases: tucatinib plus trastuzumab and capecitabine (HER2CLIMB) improved survival, including in active brain metastases; other options include T-DM1, neratinib with capecitabine, and lapatinib combinations.
HR-positive metastatic disease: maintenance endocrine therapy may accompany HER2 therapy after chemotherapy.
Up to 30% to 50% of patients with metastatic HER2-positive disease develop brain metastases, so neurologic symptom teaching is essential.
Nursing Safety Priorities
Cardiac monitoring: baseline LVEF and repeat every 3 months during trastuzumab; know the hold criteria (a drop of 16% or more from baseline, or below the lower limit of normal with a drop of 10% or more). Never give trastuzumab concurrently with an anthracycline.
Subcutaneous options: trastuzumab-hyaluronidase (600 mg every 3 weeks) and the fixed-dose pertuzumab-trastuzumab-hyaluronidase combination shorten chair time. For the combination, observe the patient for 30 minutes after the loading dose and 15 minutes after maintenance doses for hypersensitivity.
Look-alike names: trastuzumab, ado-trastuzumab emtansine, and fam-trastuzumab deruxtecan are not interchangeable . Trastuzumab biosimilars carry four-letter suffixes. Use independent double checks, tall-man lettering, and full generic names.
Pregnancy prevention: trastuzumab exposure during pregnancy can cause oligohydramnios and fetal harm; advise effective contraception during treatment and for 7 months after the last dose.
Infusion reactions: most occur with the first trastuzumab dose (fever, chills); the initial infusion runs over 90 minutes, and later infusions may run over 30 minutes if tolerated.
Scheduling and Duration Details
Total duration: HER2-directed antibody therapy is given for a total of 1 year (52 weeks), counting doses given before surgery. Every-3-week trastuzumab uses an 8 mg/kg loading dose, then 6 mg/kg.
Missed doses: per trastuzumab labeling, if an every-3-week dose is more than 1 week late, give a new 8 mg/kg loading dose before resuming 6 mg/kg. Pertuzumab is reloaded (840 mg) if 6 weeks or more have passed since the last dose.
Radiation and endocrine therapy: trastuzumab (and pertuzumab or T-DM1) can continue during radiation; endocrine therapy for HR-positive disease starts after chemotherapy and runs alongside HER2 therapy.
Cardiac holds: a held dose for LVEF decline does not change the planned total duration; therapy resumes when criteria are met.
HER2 Status Can Change
HER2 expression may be heterogeneous within a tumor, and status can change after neoadjuvant therapy or at recurrence. Residual disease and first recurrences are retested. A tumor that was HER2-positive may recur as HER2-low, and vice versa, which changes options such as trastuzumab deruxtecan.
Case Walk-Through
A 44-year-old premenopausal woman has a 3-cm ER-positive, HER2-positive cancer with a positive axillary node:
Clip the node, complete baseline echocardiogram, genetic and fertility referrals, and port placement.
Neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab for 6 cycles, with diarrhea management, neutropenia monitoring, and LVEF every 3 months.
Surgery shows residual invasive cancer, so she switches to T-DM1 for 14 cycles, with platelet and liver monitoring.
Radiation to the breast and regional nodes during T-DM1.
Endocrine therapy with ovarian function suppression because of her high risk, plus bone health monitoring and contraception counseling.
Consideration of extended neratinib after HER2 therapy ends, weighing diarrhea risk.